Metabolic / body-composition research
Limited Human Evidence
Historical investigation does not equal current approved obesity care.
Also known as Tyr-hGH fragment 177-191
Modified fragment of human growth hormone studied historically for metabolic hypotheses. Not an established approved obesity medicine.
AOD-9604 is a modified fragment of the C-terminal region of human growth hormone, investigated for fat-metabolism hypotheses without intending full GH receptor agonism of intact GH. It is not an FDA-approved obesity drug comparable to semaglutide or tirzepatide. Human evidence remains limited relative to modern incretin medicines.
AOD-9604 is a piece of growth hormone that researchers hoped might affect fat metabolism without all of GH's other actions.
It should not be confused with approved GLP-1 or GIP/GLP-1 medicines, which have large modern trial programs.
AOD-9604 is a snippet of growth hormone studied for possible effects on fat metabolism. It is not the same as taking growth hormone, and it is not an approved modern weight-management drug.
The analog was designed to capture metabolic fragments of hGH while reducing full GH-receptor/IGF-I axis agonism. Whether that design achieved a clinically useful, safe human effect remains insufficiently established compared with approved metabolic drugs.
Step 1
Peptide
AOD-9604 (hGH fragment analog)
Step 2
Proposed target
Metabolic pathways distinct from full GH agonism (hypothesis)
Step 3
Pathway
Experimental lipolysis / body-composition research
Step 4
Observed research effect
Limited/uncertain human evidence; not an approved standard therapy
Historical investigation does not equal current approved obesity care.
Some clinical investigation has occurred historically. A contemporary, labeled benefit-risk profile like Wegovy/Zepbound is not available. Treat claims conservatively.
Fragment-based lipolytic hypotheses exist in older experimental literature.
No sourced study cards have been attached yet. Information not sufficiently established at the study-card level.
Safety information may be incomplete, especially for experimental peptides.
Safety information may be incomplete, especially for experimental peptides. Consult a qualified healthcare professional for personal medical advice.
Long-term safety: Not sufficiently established.
Evidence limitations: Do not analogize trial results from semaglutide or tirzepatide to this fragment.
Administration practices vary by compound and clinical context. Follow approved prescribing information or guidance from a qualified healthcare professional. This page does not provide injection technique, mixing, or personalized dosing instructions.
These are unofficial community figures from the reconstitution calculator, used only so vial milligrams convert into U-100 units. They are not a personal AOD-9604 dose and not approved labeling.
AOD-9604
250 mcg, 300 mcg, 600 mcg
Open the peptide reconstitution calculator for AOD-9604, including mix volume and syringe units.
Discovery
complete
hGH fragment analog design.
Human studies
in progress
Historical clinical investigation; modern approval not established.
Regulatory status
not started
Not an established approved obesity drug here.
No. Different mechanism class and a much weaker, less established evidence and regulatory profile.
Metabolic Research
GLP-1 receptor agonist approved in the United States for specific diabetes and weight-management indications, depending on product and labeling.
View peptide →
Metabolic Research
Dual GIP and GLP-1 receptor agonist approved in the United States for specific diabetes and weight-related indications, depending on product labeling.
View peptide →